Comparison of published studies in which median OS in patients with clonally related and clonally unrelated RT-DLBCL has been compared by a statistical test
| Author name, y . | Intervention . | Number of patients (% clonally related) . | Median OS in clonally related patients . | Median OS in clonally unrelated patients . | Significant difference between groups (P value) . | Potential confounding factors in outcome assessment . |
|---|---|---|---|---|---|---|
| Mao et al,15 2007 | Not specified | 23 (78.3%) | Not specified | Not specified | No (not given) | Related cases were thought to have higher rates of immunoblastic morphology and unmutated IgHV (although not statistically assessed). |
| Rossi et al,10 2011 | RCHOP, 65% Fludarabine-based, 8.5% Other, 26.5% | 63 (79.4%) | 14.2 mo | 62.5 mo | Yes (P = .017) | Related RT group enriched for cases with stereotyped B-cell receptor VH CDR3 (P = .009) and TP53 disruption (P = .018). |
| Abrisqueta et al,19 2020 | RCHOP, 60% Other, 18% None, 22% | 35 (85.7%) | 5.4 mo | 74.8 mo | Yes (P = .05) | Not assessed |
| Wang et al,9 2020 | RCHOP, 65% Targeted therapies, 11% Other, 19% None, 5% | 21 (57.1%) | Not specified | Not specified | No (P = .6) | Not assessed |
| Broséus et al,23 2023 | RCHOP-like, 87% Platinum-based, 7% | 58 (75.9%) | 8 mo | 35.5 mo | Yes (P = .018) | Multivariate analysis confirmed the significance of findings when controlled for IPI, TP53 disruption, and “double-hit” RT. Related RT group was enriched for cases with more heavily pretreated CLL (P = .02), IgHV-unmutated CLL (P = 6.3 ×10–9), and MYD88wt (P = 7 ×10–3). |
| Parry et al,7 2023 | R chemotherapy, 77% Allogeneic HSCT, 8% Autologous HSCT, 7% CAR-T, 3% | 52 (86.5%) | 5.8 mo | 56.4 mo | Yes (P = .0094) | Clonally unrelated RT tended to lack TP53 and NOTCH1 disruption and have underlying CLL, which was IgHV mutated (although not statistically assessed). |
| Author name, y . | Intervention . | Number of patients (% clonally related) . | Median OS in clonally related patients . | Median OS in clonally unrelated patients . | Significant difference between groups (P value) . | Potential confounding factors in outcome assessment . |
|---|---|---|---|---|---|---|
| Mao et al,15 2007 | Not specified | 23 (78.3%) | Not specified | Not specified | No (not given) | Related cases were thought to have higher rates of immunoblastic morphology and unmutated IgHV (although not statistically assessed). |
| Rossi et al,10 2011 | RCHOP, 65% Fludarabine-based, 8.5% Other, 26.5% | 63 (79.4%) | 14.2 mo | 62.5 mo | Yes (P = .017) | Related RT group enriched for cases with stereotyped B-cell receptor VH CDR3 (P = .009) and TP53 disruption (P = .018). |
| Abrisqueta et al,19 2020 | RCHOP, 60% Other, 18% None, 22% | 35 (85.7%) | 5.4 mo | 74.8 mo | Yes (P = .05) | Not assessed |
| Wang et al,9 2020 | RCHOP, 65% Targeted therapies, 11% Other, 19% None, 5% | 21 (57.1%) | Not specified | Not specified | No (P = .6) | Not assessed |
| Broséus et al,23 2023 | RCHOP-like, 87% Platinum-based, 7% | 58 (75.9%) | 8 mo | 35.5 mo | Yes (P = .018) | Multivariate analysis confirmed the significance of findings when controlled for IPI, TP53 disruption, and “double-hit” RT. Related RT group was enriched for cases with more heavily pretreated CLL (P = .02), IgHV-unmutated CLL (P = 6.3 ×10–9), and MYD88wt (P = 7 ×10–3). |
| Parry et al,7 2023 | R chemotherapy, 77% Allogeneic HSCT, 8% Autologous HSCT, 7% CAR-T, 3% | 52 (86.5%) | 5.8 mo | 56.4 mo | Yes (P = .0094) | Clonally unrelated RT tended to lack TP53 and NOTCH1 disruption and have underlying CLL, which was IgHV mutated (although not statistically assessed). |
CAR-T, chimeric antigen receptor therapy; HSCT, hematopoietic stem cell transplant; IPI, International Prognostic Index; MYD88wt, MYD88 wild type; R, rituximab; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.